© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bluejay Diagnostics, Inc. (BJDX) stock surged +24.00%, trading at $1.24 on NASDAQ, up from the previous close of $1.00. The stock opened at $1.49, fluctuating between $1.24 and $1.69 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 05, 2026 | 1.48 | 1.69 | 1.23 | 1.24 | 90.03M |
| Aug 04, 2026 | 0.91 | 1.04 | 0.91 | 1.00 | 14.79M |
| Aug 03, 2026 | 0.86 | 1.00 | 0.86 | 0.94 | 436.46K |
| Jul 31, 2026 | 0.95 | 0.95 | 0.86 | 0.86 | 103.33K |
| Jul 30, 2026 | 0.88 | 0.95 | 0.83 | 0.93 | 183.89K |
| Jul 29, 2026 | 0.99 | 1.00 | 0.83 | 0.88 | 235.76K |
| Jul 28, 2026 | 1.05 | 1.06 | 0.96 | 1.00 | 281.09K |
| Jul 27, 2026 | 1.05 | 1.11 | 1.02 | 1.10 | 355.52K |
| Jul 24, 2026 | 1.13 | 1.13 | 1.02 | 1.03 | 234.96K |
| Jul 23, 2026 | 1.15 | 1.17 | 1.11 | 1.14 | 246.93K |
| Jul 22, 2026 | 1.07 | 1.17 | 1.03 | 1.15 | 674.03K |
| Jul 21, 2026 | 1.15 | 1.17 | 1.12 | 1.16 | 1.05M |
| Jul 20, 2026 | 1.28 | 1.34 | 1.21 | 1.21 | 725.62K |
| Jul 17, 2026 | 1.30 | 1.47 | 1.25 | 1.45 | 1.52M |
| Jul 16, 2026 | 1.31 | 1.33 | 1.25 | 1.30 | 849.97K |
| Jul 15, 2026 | 1.27 | 1.39 | 1.26 | 1.35 | 4.27M |
| Jul 14, 2026 | 1.46 | 1.56 | 1.21 | 1.25 | 17.08M |
| Jul 13, 2026 | 1.26 | 1.31 | 1.22 | 1.22 | 979.14K |
| Jul 10, 2026 | 1.38 | 1.47 | 1.33 | 1.45 | 1.99M |
| Jul 09, 2026 | 1.50 | 1.62 | 1.37 | 1.40 | 12.81M |
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
| Employees | 6 |
| Beta | 0.88 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |